EHA Library - The official digital education library of European Hematology Association (EHA)

THYROID FUNCTIONAL STATUS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA ON TKIS - SINGLE -CENTER RESULTS
Author(s):
Marina Dragičević
,
Marina Dragičević
Affiliations:
Clinic for Hematology,Novi Sad,Serbia;Faculty of Medicine, University of Novi Sad,Novi Sad,Serbia
Ivana Urošević
,
Ivana Urošević
Affiliations:
Clinic for Hematology,Novi Sad,Serbia;Faculty of Medicine, University of Novi Sad,Novi Sad,Serbia
Marina Dokić
,
Marina Dokić
Affiliations:
Clinic for Hematology,Novi Sad,Serbia;Faculty of Medicine, University of Novi Sad,Novi Sad,Serbia
Ivana Bajkin
,
Ivana Bajkin
Affiliations:
Clinic for Endocrinology, Diabetes and Metabolic Diseases,Novi Sad,Serbia;Faculty of Medicine, University of Novi Sad,Novi Sad,Serbia
Tijana Ičin
,
Tijana Ičin
Affiliations:
Clinic for Endocrinology, Diabetes and Metabolic Diseases,Novi Sad,Serbia;Faculty of Medicine, University of Novi Sad,Novi Sad,Serbia
Ivanka Perčić
,
Ivanka Perčić
Affiliations:
Clinic for Hematology,Novi Sad,Serbia;Faculty of Medicine, University of Novi Sad,Novi Sad,Serbia
Amir El Farra
Amir El Farra
Affiliations:
Clinic for Hematology,Novi Sad,Serbia;Faculty of Medicine, University of Novi Sad,Novi Sad,Serbia
(Abstract release date: 05/18/17) EHA Library. Dragičević M. 05/18/17; 182549; PB1835
Marina Dragičević
Marina Dragičević
Contributions
PDF Abstract
Abstract

Abstract: PB1835

Type: Publication Only

Background

Tyrosine kinas inhibitors (TKI) as target specific compounds profoundly changed the outcome in patients with chronic myeloid leukemia (CML). TKI-induced thyroid dysfunction is now recognized as a common toxicity associated with some TKI. In the previous decade, cases of thyroid dysfunction have been reported in patients treated with different TKIs.

Aims

To evaluate the thyroid functional status in CML patients treated with imatinib and nilotinib.

Methods
This cross-sectional study comprised 85 patients with CML in chronic phase, treated with imatinib and nilotinib, at the Clinic for Hematology, Clinical Centre of Vojvodina, Serbia. Thyroid function was assessed by analyzing the serum FT3, FT4 and TSH levels. Hypothyroidism in relation with TKI therapy was defined as newly diagnosed hypothyroidism (while the patient was already on TKI therapy) requiring hormone substitution therapy or serum fT4 level <11,5 pmol/l and TSH >5.50 mIU/l. Patients with previous medical history of thyroid dysfunction were excluded. The duration of TKI treatment varied from 2 month to 10 years. The dose of imatinib was 400mg daily, while nilotinib was dosed 800mg a day.

Results

From the total number of patients included, 37 (43,53%) were female and 48 (56,47%) were male. Mean age was 56,71 age (range 21-84). The prevalence of hypothyroidism (clinical, and subclinical) was 8,23% (n = 7) which is in accordance with the prevalence in general population. Three patients (3,53%) were diagnosed to have subclinical hypothyroidism (defined as normal serum fT4 and TSH >5.50 mIU/l). Hypothyroidism was more common in males (71,5%, p= 0,29, not statically significant). In patients treated with imatinib, 2 (3,4%) had subclinical, while 3 (5,01%) had clinical hypothyroidism. Of the 26 patients treated with nilotinib, subclinical hypothyroidism was detected in 1 (3,85%), as well as clinical hypothyroidism (3,85%). Other thyroid dysfunctions were not detected.

Conclusion
Hypothyroidism was the only thyroid dysfunction in our cross-sectional study. The prevalence of hypothyroidism in our study group did not differ from general population. Additional study on a larger sample size and evaluation of antibodies is required.

Session topic: 8. Chronic myeloid leukemia - Clinical

Keyword(s): Tyrosine kinase inhibitor, Side effects, Chronic myeloid leukemia

Abstract: PB1835

Type: Publication Only

Background

Tyrosine kinas inhibitors (TKI) as target specific compounds profoundly changed the outcome in patients with chronic myeloid leukemia (CML). TKI-induced thyroid dysfunction is now recognized as a common toxicity associated with some TKI. In the previous decade, cases of thyroid dysfunction have been reported in patients treated with different TKIs.

Aims

To evaluate the thyroid functional status in CML patients treated with imatinib and nilotinib.

Methods
This cross-sectional study comprised 85 patients with CML in chronic phase, treated with imatinib and nilotinib, at the Clinic for Hematology, Clinical Centre of Vojvodina, Serbia. Thyroid function was assessed by analyzing the serum FT3, FT4 and TSH levels. Hypothyroidism in relation with TKI therapy was defined as newly diagnosed hypothyroidism (while the patient was already on TKI therapy) requiring hormone substitution therapy or serum fT4 level <11,5 pmol/l and TSH >5.50 mIU/l. Patients with previous medical history of thyroid dysfunction were excluded. The duration of TKI treatment varied from 2 month to 10 years. The dose of imatinib was 400mg daily, while nilotinib was dosed 800mg a day.

Results

From the total number of patients included, 37 (43,53%) were female and 48 (56,47%) were male. Mean age was 56,71 age (range 21-84). The prevalence of hypothyroidism (clinical, and subclinical) was 8,23% (n = 7) which is in accordance with the prevalence in general population. Three patients (3,53%) were diagnosed to have subclinical hypothyroidism (defined as normal serum fT4 and TSH >5.50 mIU/l). Hypothyroidism was more common in males (71,5%, p= 0,29, not statically significant). In patients treated with imatinib, 2 (3,4%) had subclinical, while 3 (5,01%) had clinical hypothyroidism. Of the 26 patients treated with nilotinib, subclinical hypothyroidism was detected in 1 (3,85%), as well as clinical hypothyroidism (3,85%). Other thyroid dysfunctions were not detected.

Conclusion
Hypothyroidism was the only thyroid dysfunction in our cross-sectional study. The prevalence of hypothyroidism in our study group did not differ from general population. Additional study on a larger sample size and evaluation of antibodies is required.

Session topic: 8. Chronic myeloid leukemia - Clinical

Keyword(s): Tyrosine kinase inhibitor, Side effects, Chronic myeloid leukemia

Premium Sponsors

What's new at EHA

Browse the open-source material from EHA past Congresses and meetings.

References

EHA Terms & Conditions
2025 ©
European Hematology Association
USER TERMS AND CONDITIONS / PRIVACY POLICY
(Amended according to GDPR)

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies